DaniellHW: Hypogonadism in men consuming sustained-action oral opioids. J Pain, 2002; 3:377–384.
7.
FraserLA, et al.: Oral opioids for chronic non-cancer pain: Higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes, 2009; 117:38–43.
8.
BhasinS, et al.: Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2010; 95:2536–2559.
9.
SnyderPJ, et al.: Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab, 2000; 85:2670–2677.
10.
DaniellHW, LentzR, MazerNA: Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain, 2006; 7:200–210.
11.
TraishA, GuayAT, SparkRF: Are the Endocrine Society's Clinical Practice Guidelines on Androgen Therapy in Women misguided? A commentary. J Sex Med, 2007; 4:1223–1235.
12.
VigenR, et al.: Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA, 2013; 310:1829–1836.
13.
FinkleWD, et al.: Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One, 2014; 9:e85805.
14.
US FDA: “FDA adding general warning to testosterone products about potential for venous blood clots.” Silver Spring, MD: FDA, 2014.
